Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Liquidia Corp stock (US53634H1077): Is the PRINT pipeline strong enough to unlock new upside?
Liquidia Corp (US53634H1077) is a biotech company specializing in inhaled therapies for pulmonary diseases, utilizing its proprietary PRINT technology for precise drug delivery. The company’s lead drug, YUTREPIA, targets the significant pulmonary arterial hypertension (PAH) market and is nearing key milestones. While promising, investors should consider risks such as ongoing patent disputes, potential dilution, and the need for successful commercialization.